A Phase 3 interventional study of Roflumilast and Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 179 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-01-16.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 16 in phase 3, and was the 7th registered.
5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:
Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 17 · Phase 4 8
First in 2003; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,523 is above the median of 62 across 3,841 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 154 across the 32 interventional studies. Of the 30 that completed or were terminated, 17 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 32 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca: 14 open now, 15 under way, 4 of them phase 3. Of 264 finished, 127 (48%) have results posted.
Among the 284 studies in Pulmonary Disease, Chronic Obstructive by AstraZeneca, this one is the 22nd largest by enrollment of the 194 interventional ones that give a count, is one of 9 that started in 2006, is one of 76 in phase 3, and was the 12th registered.
AstraZeneca’s Pulmonary Disease, Chronic Obstructive studies by the year they started, since 1999.
1 of the studies testing roflumilast in Pulmonary Disease, Chronic Obstructive that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07795086Sidra AzizComparative Effectiveness of Roflumilast and Azithromycin in Reducing Exacerbations in Severe Chronic Obstructive Pulmonary Disease ( COPD ) Patients With Chronic Bronchitis Phenotype | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among AstraZeneca’s 284 in Pulmonary Disease, Chronic Obstructive:
This tab as a report to print or save as PDF → With an account.
The aim of the study is to investigate the effect of roflumilast on exacerbation rate and pulmonary function in patients with chronic obstructive pulmonary disease (COPD). Roflumilast will be administered orally once daily in the morning at one dose level. The study duration will last up to 56 weeks. The study will provide further data on safety and tolerability of roflumilast.
For additional information (for US patients only) see www.COPDSTUDY.net or dial 866-788-2673 (toll free).
Main Inclusion Criteria:
Main Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
500 mcg, once daily, oral administration in the morning
Drug: Roflumilast
once daily
Drug: Placebo
500 mcg, once daily, oral administration in the morning
once daily
Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)
Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \[L\]
Time frame: Change from baseline over 52 weeks of treatment
COPD Exacerbation Rate (Moderate or Severe)
Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\].
Time frame: 52 weeks treatment period
Post-bronchodilator FEV1 [L]
Mean change from baseline during the treatment period in post-bronchodilator FEV1 \[L\]
Time frame: Change from baseline over 52 weeks of treatment
Time to Mortality Due to Any Reason
Time frame: 52 weeks treatment period
Natural Log-transformed C-reactive Protein (CRP)
Mean change from baseline to the last post randomization measurement in natural log-transformed CRP
Time frame: Change from baseline to last post randomization measurement (52 weeks)
Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period
The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.
Time frame: Change from baseline over 52 weeks of treatment
| Milestone | Roflumilast | Placebo |
|---|---|---|
| Started | 765 | 758 |
| Completed | 502 | 525 |
| Not completed | 263 | 233 |
Mean change from baseline during the treatment period in pre-bronchodilator FEV1 \[L\]
| mL | Roflumilast | Placebo |
|---|---|---|
| Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) | 46 ± 8 | 8 ± 8 |
Mean rate of COPD exacerbations requiring oral or parenteral glucocorticosteroids (=moderate COPD exacerbations), or requiring hospitalization, or leading to death (=severe COPD exacerbations), per patient per year. A COPD exacerbation is an event in the natural course of the disease characterized by a change in the patient's baseline dyspnea, cough and/or sputum beyond day-to-day variability sufficient to warrant a change in management \[American Thoracic Society (ATS) / European Respiratory Society (ERS) 2005\].
| exacerbations per patient per year | Roflumilast | Placebo |
|---|---|---|
| COPD Exacerbation Rate (Moderate or Severe) | 1.077 (0.960 to 1.207) | 1.266 (1.141 to 1.404) |
Mean change from baseline during the treatment period in post-bronchodilator FEV1 \[L\]
| mL | Roflumilast | Placebo |
|---|---|---|
| Post-bronchodilator FEV1 [L] | 57 ± 9 | 8 ± 8 |
| days | Roflumilast | Placebo |
|---|---|---|
| Time to Mortality Due to Any Reason | 213.8 ± 118.9 | 207.5 ± 108.5 |
Mean change from baseline to the last post randomization measurement in natural log-transformed CRP
| mg/L | Roflumilast | Placebo |
|---|---|---|
| Natural Log-transformed C-reactive Protein (CRP) | 1.0475 (0.9584 to 1.1450) | 1.1003 (1.0071 to 1.2021) |
The TDI is a recognized questionnaire to measure dyspnea in an out patient COPD population. At baseline, 3 components of dyspnea, each graded with 4 questions, were asked: - Functional Impairment - Magnitude of Task - Magnitude of Effort At each of the post-randomization visits questions from the TDI were asked related to 3 components: Change in - Functional Impairment - Magnitude of Task - Magnitude of Effort Each question in the TDI is graded from -3 (major deterioration) to +3 (major improvement). This results in a TDI Focal Score ranging from -9 to +9.
| scores on a scale | Roflumilast | Placebo |
|---|---|---|
| Mean Transition Dyspnea Index (TDI) Focal Score During the Treatment Period | 0.658 ± 0.084 | 0.426 ± 0.082 |
Collected over 52 weeks treatment period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Roflumilast | — | 144/769 (18.7%) | 232/769 (30.2%) |
| Placebo | — | 153/755 (20.3%) | 136/755 (18%) |
| Event | Roflumilast | Placebo |
|---|---|---|
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 70/769 | 82/755 |
| PneumoniaInfections and infestations | 8/769 | 11/755 |
| Atrial fibrillationCardiac disorders | 7/769 | 0/755 |
| Cardiac failureCardiac disorders | 1/769 | 4/755 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/769 | 3/755 |
| Cardiac failure congestiveCardiac disorders | 1/769 | 3/755 |
| Acute myocardial infarctionCardiac disorders | 0/769 | 3/755 |
| SyncopeNervous system disorders | 3/769 | 2/755 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 2/769 | 2/755 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/769 | 2/755 |
| Event | Roflumilast | Placebo |
|---|---|---|
| Weight decreasedInvestigations | 92/769 | 24/755 |
| DiarrhoeaGastrointestinal disorders | 62/769 | 26/755 |
| NasopharyngitisInfections and infestations | 57/769 | 50/755 |
| NauseaGastrointestinal disorders | 40/769 | 15/755 |
| BronchitisInfections and infestations | 33/769 | 39/755 |
| Age, Continuous(years) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Mean | 63.53 ± 9.5 | 63.36 ± 9.2 | 63.45 ± 9.4 |
| Gender(Participants) | Roflumilast | Placebo | Total |
|---|---|---|---|
| Female | 225 | 220 | 445 |
| Male | 540 | 538 | 1078 |
Showing the first 100 of 179 sites across 11 countries. Choose a country and city above to see the rest.
The record gives a start of Feb 2006, a primary completion of Jul 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Roflumilast
Pulmonary Disease, Chronic Obstructive →